Semaglutide
-
healthGLP-1 Medications Linked to Improved Male Fertility and Testosterone Levels
New research presented at ENDO 2026 suggests GLP-1 weight-loss drugs may improve testosterone and sperm quality in obese men, offering a fertility-preserving alternative to traditional hormone replacement therapy.
-
healthGLP-1 Weight Loss Drugs Drive Surge in Cosmetic Body Contouring Procedures
Rapid weight loss from GLP-1 medications like Ozempic is causing sagging skin and volume loss, prompting a significant increase in plastic surgery and body contouring procedures nationwide.
-
healthUK Approves First Daily Oral GLP-1 Semaglutide for Obesity Treatment
Novo Nordisk secures UK approval for daily oral semaglutide, offering a non-injectable alternative for obesity management with significant weight loss results in clinical trials.
-
healthGLP-1 Drugs Show Promise for Joint and Bone Health Beyond Weight Loss
New research highlights how GLP-1 receptor agonists may protect cartilage, bone, and muscle, offering therapeutic potential for osteoarthritis and back pain.
-
healthGLP-1 Therapies: Bone, Joint & Muscle Effects Beyond Weight Loss
Experts examine the complex musculoskeletal impact of GLP-1 drugs, from bone density to sarcopenia, at the ESCEO symposium.
-
healthGLP-1 Drugs Linked to Lower Breast Cancer Risk and Better Outcomes
Observational studies show GLP-1 meds like Ozempic may reduce breast cancer incidence by 30% and improve survival rates.
-
healthSemaglutide Boosts Quality of Life in Diabetes and Kidney Disease Patients
New FLOW trial data shows semaglutide improves daily functioning and well-being in adults with type 2 diabetes and chronic kidney disease.
-
healthCanada Approves Generic Ozempic; US Waits Until 2032
Canada becomes first G7 nation to approve generic semaglutide. US patients face patent barriers until 2032, sparking cross-border interest.